Citigroup Lowers Zoetis (NYSE:ZTS) Price Target to $96.00

Zoetis (NYSE:ZTS) had its price objective dropped by stock analysts at Citigroup from $112.00 to $96.00 in a note issued to investors on Tuesday,Benzinga reports. The brokerage currently has a “buy” rating on the stock. Citigroup’s price target points to a potential upside of 27.60% from the company’s previous close.

Other equities analysts have also issued research reports about the company. JPMorgan Chase & Co. lowered their price target on Zoetis from $130.00 to $115.00 and set an “overweight” rating for the company in a research report on Friday. Argus reissued a “hold” rating on shares of Zoetis in a research report on Wednesday, May 27th. UBS Group reduced their price objective on shares of Zoetis from $85.00 to $80.00 and set a “neutral” rating for the company in a research note on Friday. TD Cowen decreased their target price on shares of Zoetis from $150.00 to $104.00 and set a “buy” rating for the company in a report on Tuesday, June 30th. Finally, HSBC dropped their target price on shares of Zoetis from $140.00 to $95.00 and set a “buy” rating on the stock in a research note on Monday, July 6th. Eight equities research analysts have rated the stock with a Buy rating, nine have assigned a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the stock has an average rating of “Hold” and a consensus price target of $109.62.

Zoetis Stock Up 0.5%

Shares of ZTS traded up $0.41 during mid-day trading on Tuesday, reaching $75.23. The company had a trading volume of 3,132,580 shares, compared to its average volume of 5,799,756. The company has a debt-to-equity ratio of 2.87, a quick ratio of 1.84 and a current ratio of 3.08. The company has a market capitalization of $31.54 billion, a price-to-earnings ratio of 12.39, a price-to-earnings-growth ratio of 1.21 and a beta of 0.73. The firm has a 50-day moving average price of $76.60 and a 200 day moving average price of $100.24. Zoetis has a 52 week low of $71.45 and a 52 week high of $160.48.

Zoetis (NYSE:ZTS) last posted its quarterly earnings data on Thursday, August 6th. The company reported $1.87 earnings per share for the quarter, beating analysts’ consensus estimates of $1.85 by $0.02. Zoetis had a return on equity of 74.89% and a net margin of 27.49%.The company had revenue of $2.47 billion during the quarter, compared to analyst estimates of $2.50 billion. During the same quarter last year, the company earned $1.76 EPS. The firm’s revenue for the quarter was down .2% on a year-over-year basis. Zoetis has set its FY 2026 guidance at 6.150-6.250 EPS. On average, sell-side analysts forecast that Zoetis will post 6.43 EPS for the current year.

Insider Activity

In related news, Director Frank A. Damelio purchased 6,650 shares of the company’s stock in a transaction dated Wednesday, May 13th. The shares were purchased at an average price of $75.39 per share, with a total value of $501,343.50. Following the acquisition, the director directly owned 21,458 shares in the company, valued at $1,617,718.62. The trade was a 44.91% increase in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Paul Bisaro purchased 2,000 shares of Zoetis stock in a transaction dated Wednesday, May 13th. The stock was bought at an average price of $75.88 per share, with a total value of $151,760.00. Following the completion of the purchase, the director directly owned 27,862 shares of the company’s stock, valued at approximately $2,114,168.56. This trade represents a 7.73% increase in their ownership of the stock. Additional details regarding this purchase are available in the official SEC disclosure. 0.22% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Zoetis

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. J. Stern & Co. LLP lifted its holdings in shares of Zoetis by 12,431.2% during the 4th quarter. J. Stern & Co. LLP now owns 24,069,492 shares of the company’s stock valued at $3,028,423,000 after buying an additional 23,877,416 shares during the period. Norges Bank purchased a new stake in Zoetis during the fourth quarter valued at $734,425,000. Vanguard Group Inc. increased its position in Zoetis by 12.9% during the fourth quarter. Vanguard Group Inc. now owns 47,780,974 shares of the company’s stock valued at $6,011,802,000 after acquiring an additional 5,474,210 shares during the last quarter. Flossbach Von Storch SE bought a new position in Zoetis in the second quarter valued at about $302,601,000. Finally, BlackRock Inc. lifted its holdings in Zoetis by 10.8% in the second quarter. BlackRock Inc. now owns 39,430,181 shares of the company’s stock valued at $2,833,453,000 after acquiring an additional 3,845,869 shares during the period. Hedge funds and other institutional investors own 92.80% of the company’s stock.

Trending Headlines about Zoetis

Here are the key news stories impacting Zoetis this week:

• Positive Sentiment: BNP Paribas Exane lowered its price target to $110 from $146 but retained an “outperform” rating. The new target still implies approximately 46.5% upside, signaling that the firm views Zoetis’ recent weakness as excessive. Tickerreport article
• Neutral Sentiment: Analyst coverage remains divided. JPMorgan reportedly reduced its price target to $115, while broader commentary continues to assess whether Wall Street is bullish or bearish on Zoetis. The target remains well above the current trading level, but the cuts point to more cautious expectations. JPMorgan price target article
• Neutral Sentiment: Zoetis’ incoming finance chief is expected to take on responsibilities similar to a chief operating officer, reflecting a broader trend of companies combining CFO and COO duties. The change could improve operational oversight, although investors may initially view it as part of a broader leadership transition. Fortune leadership article
• Negative Sentiment: Piper Sandler cut its target to $80 from $90 and shifted to a “neutral” rating, leaving only about 6.5% implied upside. Analysts cited competitive pressures and leadership changes as factors shaping the outlook. Benzinga analyst update
• Negative Sentiment: Recent commentary highlights investor concerns after Zoetis’ latest quarter: earnings modestly exceeded estimates, but revenue slightly missed forecasts and declined year over year. Fiscal 2026 EPS guidance of $6.15–$6.25 is also below the roughly $6.43 analyst consensus, reinforcing worries about slower growth and competitive pressure. Yahoo Finance Zoetis Q2 deep dive

Zoetis Company Profile

Zoetis Inc (NYSE: ZTS) is a global animal health company that develops, manufactures and markets a broad portfolio of products and services for companion animals and livestock. The company’s offerings include pharmaceuticals, vaccines and biologics, parasiticides and anti-infectives, as well as diagnostic instruments, consumables and laboratory testing services. Zoetis serves the veterinary community, livestock producers and other animal-health customers with products designed to prevent, detect and treat disease and to support animal productivity and welfare.

Zoetis traces its roots to the animal health business of Pfizer and became an independent, publicly traded company following a 2013 separation and initial public offering.